Trinity Biotech Statistics
Want to see TRIB full AI Analyst Report?
Trinity Biotech (TRIB) Stock Statistics & Valuation Metrics
Total Valuation
Trinity Biotech has a market cap or net worth of $3.79M. The enterprise value is $147.58M.
- Market Cap
- $3.79M
- Enterprise Value
- $147.58M
Share Statistics
Trinity Biotech has 813,132 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 813,132
- Owned by Insiders
- ―
- Owned by Institutions
- 3.12%
Financial Efficiency
Trinity Biotech’s return on equity (ROE) is 0.52 and return on invested capital (ROIC) is -15.27%.
- Return on Equity (ROE)
- 0.52
- Return on Assets (ROA)
- -0.36
- Return on Invested Capital (ROIC)
- -15.27%
- Return on Capital Employed (ROCE)
- 0.32
- Revenue Per Employee
- 152.56K
- Profits Per Employee
- -130.23K
- Employee Count
- 287
- Asset Turnover
- 0.42
- Inventory Turnover
- 1.43
Valuation Ratios
The current PE Ratio of Trinity Biotech is -0.13. Trinity Biotech’s PEG ratio is -0.00.
- PE Ratio
- -0.13
- PS Ratio
- 3.25
- PB Ratio
- -0.05
- Price to FCF
- -35.43
- Price to Operating Cash Flow
- -1.10
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Trinity Biotech had revenue of 43.78M and earned -37.38M in profits. Earnings per share was -60.00.
- Revenue
- 43.78M
- Gross Profit
- 16.89M
- Operating Income
- -11.42M
- Pretax Income
- -37.18M
- Net Income
- -37.38M
- EBITDA
- -21.38M
- Earnings Per Share (EPS)
- -60.00
Cash Flow
In the last 12 months, operating cash flow was -6.26M and capital expenditures -88,261, giving a free cash flow of -6.34M billion.
- Operating Cash Flow
- -6.26M
- Free Cash Flow
- -6.34M
- Free Cash Flow per Share
- -5.36
Dividends & Yields
Trinity Biotech pays an annual dividend of $33.00, resulting in a dividend yield of ―
- Dividend Per Share
- $33.00
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.90%
- Earnings Yield
- -813.00%
Stock Price Statistics
- Beta
- 2.86
- 52-Week Price Change
- -78.45%
- 50-Day Moving Average
- 7.31
- 200-Day Moving Average
- 14.72
- Relative Strength Index (RSI)
- 39.60
- Average Volume (3m)
- 17.58K
Important Dates
Trinity Biotech upcoming earnings date is Dec 10, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Sep 03, 2026
- Next Earnings Date
- Dec 10, 2026
- Ex-Dividend Date
- Jun 05, 2015
Financial Position
Trinity Biotech as a current ratio of 0.25, with Debt / Equity ratio of -191.69%
- Current Ratio
- 0.25
- Quick Ratio
- 0.12
- Debt to Market Cap
- 8.65
- Net Debt to EBITDA
- -6.21
- Interest Coverage Ratio
- -0.87
Taxes
In the past 12 months, Trinity Biotech has paid 199.00K in taxes.
- Income Tax
- 199.00K
- Effective Tax Rate
- -0.01
Enterprise Valuation
Trinity Biotech EV to EBITDA ratio is -55.39, with an EV/FCF ratio of -74.46.
- EV to Sales
- 6.83
- EV to EBITDA
- -55.39
- EV to Free Cash Flow
- -74.46
- EV to Operating Cash Flow
- -75.19
Balance Sheet
Trinity Biotech has $5.14M in cash and marketable securities with $137.98M in debt, giving a net cash position of -$132.84M billion.
- Cash & Marketable Securities
- $5.14M
- Total Debt
- $137.98M
- Net Cash
- -$132.84M
- Net Cash Per Share
- -$163.37
- Tangible Book Value Per Share
- -$207.71
Margins
Gross margin is 38.48%, with operating margin of -17.97%, and net profit margin of -78.88%.
- Gross Margin
- 38.48%
- Operating Margin
- -17.97%
- Pretax Margin
- -78.33%
- Net Profit Margin
- -78.88%
- EBITDA Margin
- -12.32%
- EBIT Margin
- -17.97%
Analyst Forecast
The average price target for Trinity Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -13.28%
- EPS Growth Forecast
- 39.65%
Scores
- Smart Score
- ―
- AI Score
- 42
